2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

4:30PM-6:00PM: Abstract Number: 1894

Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Initiating Biologic and Non-biologic DMARDs, a Population-based Study

4M117: RA – Treatments III: Cardiovascular Disease & Readmissions (1890–1895)

4:30PM-6:00PM: Abstract Number: 1877

Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial

4M114: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (1872–1877)

4:30PM-6:00PM: Abstract Number: 1920

School Nurse Education for Juvenile Idiopathic Arthritis

4M125: Pediatric Rheumatology: Outcomes & Quality of Life (1920–1925)

4:30PM-6:00PM: Abstract Number: 1901

Serious Infections in Offspring Exposed in Utero to Non-TNFi Biologics and Tofacitinib

4M118: Reproductive Issues in Rheumatic Disorders (1896–1901)

4:30PM-6:00PM: Abstract Number: 1888

Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA

4M116: RA – Diagnosis, Manifestations, & Outcomes III: Diagnosis & Prognosis (1884–1889)

4:30PM-6:00PM: Abstract Number: 1897

Sexual Function and Health-related Quality of Life in Male Patients with Systemic Lupus Erythematosus, the Untold Story

4M118: Reproductive Issues in Rheumatic Disorders (1896–1901)

4:30PM-6:00PM: Abstract Number: 1899

sFlt-1, PlGF and VEGF in the Differential Diagnosis Between Active SLE Nephritis During Pregnancy and Preeclampsia

4M118: Reproductive Issues in Rheumatic Disorders (1896–1901)

4:30PM-6:00PM: Abstract Number: 1905

Sicca/Sjögren Syndrome Triggered by PD-1/PD-L1 Checkpoint Inhibitors: Data from the International ImmunoCancer Registry (ICIR)

4M119: Sjögrenʼs Syndrome – Basic & Clinical Science (1902–1907)

4:30PM-6:00PM: Abstract Number: 1893

Statin Exposure Moderates the Effects of Chronic Inflammation on Coronary Atherosclerosis Progression and Cardiovascular Events in Rheumatoid Arthritis

4M117: RA – Treatments III: Cardiovascular Disease & Readmissions (1890–1895)

4:30PM-6:00PM: Abstract Number: 1875

Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study

4M114: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (1872–1877)

4:30PM-6:00PM: Abstract Number: 1902

Systems Biology in 874 Patients with Primary Sjögren’s Syndrome Indicates the Predominant Role of Interferon Alpha Compared to Interferon Gamma, Its Association with Systemic Complications, and a New Aspect of the Genetic Contribution of HLA

4M119: Sjögrenʼs Syndrome – Basic & Clinical Science (1902–1907)

4:30PM-6:00PM: Abstract Number: 1911

Targeting the Oxidative Stress Pathway in Experimental Spondyloarthritis Reduces Pro-inflammatory Response in Rat Macrophages and Modulates Their Metabolic Requirements

4M121: Spondyloarthritis Including Psoriatic Arthritis – Clinical IV: Axial Spondyloarthritis Translational Research (1908–1913)

4:30PM-6:00PM: Abstract Number: 1856

Tenosynovial Aspiration by Ultrasound Guidance: Correlation and Diagnostic Implications of Tenosynovial Analysis and Ultrasound Doppler Signal

4M111: Imaging of Rheumatic Diseases I (1854–1859)

4:30PM-6:00PM: Abstract Number: 1851

The Association of Discrimination and Stress on Cardiovascular Disease in a Population-Based Cohort with Systemic Lupus Erythematosus

4M110: Healthcare Disparities in Rheumatology (1848–1853)

4:30PM-6:00PM: Abstract Number: 1879

The Relation of Pain Sensitization and Conditioned Pain Modulation to Pain Patterns in Knee Osteoarthritis: The Multicenter Osteoarthritis Study

4M115: Pain Mechanisms – Basic & Clinical Science (1878–1883)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].